.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Deloitte
US Department of Justice
US Army
Cipla
Cantor Fitzgerald
Argus Health
Farmers Insurance
AstraZeneca
Mallinckrodt

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Subscribe

« Back to Dashboard

Details for Patent: ➤ Subscribe

Title:Diclofenac topical formulation
Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.
Inventor(s): Kisak; Ed (San Diego, CA), Singh; Jagat (Toronto, CA)
Assignee: HZNP LIMITED (Pembroke, BM)
Filing Date:May 06, 2015
Application Number:14/705,636
Claims:1. A method for treating pain, said method comprising: administering on a long term basis a formulation, the formulation comprising: diclofenac sodium present at 2% w/w; DMSO present at 25% to 60% w/w; and a viscosity of 500-5000 centipoise, wherein the administration of the formulation is twice daily, to thereby effectively treat pain.

2. The method of claim 1, wherein the formulation consists essentially of: 30-60% w/w of DMSO; 1-15% w/w of propylene glycol; 1-30% w/w of ethanol; optionally glycerine; water; and at least one thickening agent selected from the group consisting of a cellulose polymer, a carbomer polymer, a carbomer derivative, a cellulose derivative, and mixtures thereof.

3. The method of claim 2, wherein the concentration of DMSO is about 40% to about 50% w/w.

4. The method of claim 3, wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between.

5. The method of claim 2, wherein the concentration of ethanol is present at 23-29% w/w.

6. The method of claim 2, wherein the at least one thickening agent is selected from the group consisting of a carbomer polymer, a carbomer derivative and mixtures thereof.

7. The method of claim 6, wherein the at least one thickening agent is selected from the group consisting of carbopol 971, carbopol 981, carbopol 941, carbopol 1342 and ultrez 10 .

8. The method of claim 7, wherein glycerine is present.

9. The method of claim 2, wherein the at least one thickening agent is selected from the group consisting of a cellulose polymer, a cellulose derivative, and mixtures thereof.

10. The method of claim 9, wherein the at least one thickening agent is hydroxypropyl cellulose.

11. The method of claim 10, wherein the formulation consists essentially of comprises: 2% w/w diclofenac sodium; 40-50% w/w of DMSO; 23-29% w/w of ethanol; hydroxypropyl cellulose; water: and 10-12% w/w of propylene glycol.

12. The method of claim 11, wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between.

13. The method of claim 1, wherein the formulation has improved absorption on a per dose basis compared to a comparative liquid composition.

14. The method of claim 1, wherein the pain is due to osteoarthritis.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Teva
Boehringer Ingelheim
Deloitte
Cipla
Express Scripts
Novartis
McKesson
Harvard Business School
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot